Medicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Medicus Pharma (NASDAQ:MDCX) from a strong sell rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other equities analysts have also weighed in on the stock. Alliance Global Partners reiterated a “buy” rating on shares of Medicus Pharma in a report on Monday, September 14th. Weiss Ratings raised shares of Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Medicus Pharma currently has an average rating of “Moderate Buy” and an average price target of $450.00.

Medicus Pharma Trading Up 2.7%

Shares of MDCX stock opened at $1.93 on Friday. Medicus Pharma has a 12 month low of $1.78 and a 12 month high of $127.50. The company has a market capitalization of $2.43 million, a P/E ratio of -0.02 and a beta of 0.30. The stock has a 50 day moving average of $7.04 and a two-hundred day moving average of $23.08.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($10.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.38) by ($4.12). Sell-side analysts predict that Medicus Pharma will post -36.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medicus Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Interchange Capital Partners LLC lifted its holdings in Medicus Pharma by 33.9% during the 3rd quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock worth $343,000 after purchasing an additional 538,039 shares in the last quarter. Sterling Investment Advisors Ltd. purchased a new position in Medicus Pharma in the 2nd quarter worth $45,000. Finally, Private Advisor Group LLC boosted its holdings in shares of Medicus Pharma by 36.8% during the first quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock worth $110,000 after purchasing an additional 64,560 shares during the period.

About Medicus Pharma

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.